Lung involvement reduces life expectancy in systemic scleroderma
Statement (e) is correct: lung involvement, particularly interstitial lung disease (ILD), is a major determinant of mortality and significantly reduces life expectancy in systemic sclerosis. 1
Analysis of Each Statement
a) Cardiovascular manifestations as primary diagnostic feature - INCORRECT
Systemic sclerosis diagnosis is not typically made based on cardiovascular manifestations. The disease is characterized by the triad of autoimmunity, vasculopathy, and fibrosis affecting skin and internal organs 2. Early diagnostic features include Raynaud's phenomenon, anti-nuclear antibodies, and pathologic capillaroscopy 3. Cardiovascular involvement occurs but is not the presenting or diagnostic feature.
b) Musculoskeletal involvement as diagnostic trigger - INCORRECT
While musculoskeletal manifestations can occur in SSc, the diagnosis is typically made based on skin involvement (extent determines limited vs. diffuse cutaneous subtypes), Raynaud's phenomenon, specific autoantibodies, and capillaroscopy findings 3. Musculoskeletal symptoms are not the primary diagnostic criterion.
c) No associated antibody - INCORRECT
This is definitively false. Systemic sclerosis is strongly associated with specific autoantibodies that help define clinical subsets and predict organ involvement patterns 1. The presence of anti-nuclear antibodies is one of the early diagnostic signs 3, and specific antibodies correlate with disease subtypes and prognosis 1.
d) Renal crisis caused by glomerulonephritis - INCORRECT
Scleroderma renal crisis (SRC) is not caused by glomerulonephritis. The pathophysiology involves vasculopathy and vascular changes in the kidney, not a primary glomerular inflammatory process 2. The evidence discusses SRC as a distinct complication requiring specific monitoring and management 4.
e) Lung involvement reduces life expectancy - CORRECT
Interstitial lung disease is explicitly recognized as a crucial disease manifestation that drives morbidity and mortality in systemic sclerosis 1. The 2023 EULAR recommendations emphasize ILD as one of the key fibrotic manifestations requiring aggressive treatment, with multiple therapeutic options now recommended including mycophenolate mofetil, nintedanib, rituximab, and tocilizumab 1.
The evidence demonstrates that:
- Type and severity of organ involvement drive the heterogeneous prognosis 1
- SSc remains the rheumatic disease with the highest morbidity and mortality 1
- The overall prognosis is strongly influenced by visceral manifestations, particularly pulmonary involvement 1
- Extensive research and treatment recommendations focus specifically on SSc-ILD, reflecting its critical impact on survival 4, 1
The substantial evidence base for treating SSc-ILD with immunosuppressive agents (cyclophosphamide, mycophenolate) and antifibrotic therapy (nintedanib) underscores the life-threatening nature of pulmonary involvement 4.